COMMUNIQUÉS West-GlobeNewswire

BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
10/03/2026
BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L1 1 /VEGF-A bispecific [...]
BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030
10/03/2026
BioNTech continues to sharpen its strategic focus on the growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA candidates BioNTech co-founders Ugur Sahin and Özlem Türeci will establish an [...]
EVAA.AI Expands to Integrate with Multiple Eye Care EHR Systems
10/03/2026
Eye care practices can now access EVAA’s AI-powered billing automation and clinical documentation tools without changing their existing EHR system PORTLAND, Ore., March 10, 2026 (GLOBE NEWSWIRE) -- EVAA.AI , part of the [...]
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day
10/03/2026
BPL‑003 holds Breakthrough Therapy Designation and is supported by positive Phase 2b results in treatment-resistant depression Cash runway reaffirmed through the planned early-2029 topline readouts from both parallel [...]
MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers
10/03/2026
Selected as a C-Further program with up to ~$1.1 million in non-dilutive, aggregate payments to advance IND-enabling development, with potential for meaningful double-digit downstream commercial revenue participation [...]
TECVAYLI®▼ (teclistamab) monotherapy application submitted to the EMA for relapsed/refractory multiple myeloma after at least one prior therapy
10/03/2026
Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy 1 Teclistamab monotherapy delivered superior progression-free survival and overall [...]
EnteroBiotix Announces Completion of Enrolment in Phase 2a Trial Evaluating EBX-102-02 Prior to Allogeneic Stem Cell Transplantation
10/03/2026
GLASGOW, United Kingdom, March 10, 2026 (GLOBE NEWSWIRE) -- EnteroBiotix, a clinical-stage biopharmaceutical company developing best-in-class microbiome therapies, today announced that the investigator-initiated Phase [...]
Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors
10/03/2026
Phase I results demonstrate favorable safety, sustained target engagement, and early signs of anti-tumor activity Reinforce EP4 receptor antagonism as a validated, high-value strategy to overcome immunotherapy [...]
Press Release Biocartis NV: Biocartis Receives European IVDR Certification for the Idylla™ CDx MSI Test
10/03/2026
PRESS RELEASE 10/03/2025, 08:00 CET Biocartis Receives European IVDR Certification for the Idylla™ CDx MSI Test Idylla™ CDx MSI Test is the Second Fully Automated Companion Diagnostic Test Approval for Biocartis under [...]
OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of Strategic Growth
10/03/2026
Nantes, France, March 10, 2026 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced the transition of Marc Le Bozec from interim to permanent Chief Executive Officer, effective [...]
OSE Immunotherapeutics confirme Marc Le Bozec comme Directeur Général pour mener la prochaine phase de croissance stratégique
10/03/2026
Nantes, France, 10 mars 2026 – 7h30 CET – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnemo : OSE) annonce aujourd’hui la transition de Marc Le Bozec de Directeur Général par intérim à Directeur Général permanent, [...]
Idorsia expands QUVIVIQ’s global footprint through new partnership with Pharmalink
10/03/2026
Idorsia and Pharmalink enter into an exclusive distribution and commercialization agreement for QUVIVIQ ™ (daridorexant) in the United Arab Emirates (UAE), Kuwait, Qatar, Oman, and Bahrain Allschwil, Switzerland – March [...]
Santhera Appoints Marc Clausse as Chief Commercial Officer to Lead Next Phase of Growth
10/03/2026
Pratteln, Switzerland, March 10, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces the appointment of Marc Clausse as Chief Commercial Officer (CCO), effective June 1, 2026. He succeeds Geert Jan van Daal, who will [...]
Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025
10/03/2026
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025 Financial Highlights Total Medical Device sales rose by [...]
Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option
10/03/2026
$12 Million of Tranche Warrants Potential Financing Within One Year From Closing SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a [...]
Nebu Ease Portable Nebulizer Claims Evaluated: 2026 Consumer Research Report on Mesh Nebulizer Technology, Respiratory Comfort Features, and What Buyers Should Verify
10/03/2026
A 2026 informational consumer research report examining portable nebulizer technology, vibrating mesh atomization systems, respiratory comfort features, pricing transparency, and verification considerations for adults [...]
ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives
10/03/2026
Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the following link: https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html [...]
TrimRx Telehealth Weight Loss Platform Examined in 2026 Consumer Research Report on GLP-1 Medication Access, Pricing Transparency and Safety Considerations
09/03/2026
An Informational Analysis of TrimRx Compounded Semaglutide and Tirzepatide Programs, Telehealth Prescription Process, Published Pricing Disclosures, Pharmacy Partnerships and Patient Safety Information for 2026 San [...]
Sherry Cummings, CEO of Gryphon Healthcare, Named One of the Top 50 Women to KNOW in Texas
09/03/2026
HOUSTON, March 09, 2026 (GLOBE NEWSWIRE) -- Sherry Cummings, Chief Executive Officer of Gryphon Healthcare , has been named one of the 2026 Women to KNOW in Texas , a prestigious statewide honor recognizing women who [...]

Pages